Glucagon-like Peptide-1 analogues and delipidation of coronary atheroma in statin-treated type 2 diabetic patients with coronary artery disease: The prespecified sub-analysis of the OPTIMAL randomized clinical trial
Background and aims: Randomized clinical trials have demonstrated the ability of glucagon-like peptide-1 analogues (GLP-1RAs) to reduce atherosclerotic cardiovascular disease events in patients with type 2 diabetes (T2D). How GLP-1RAs modulate diabetic atherosclerosis remains to be determined yet. M...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-06-01
|
| Series: | Atherosclerosis Plus |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2667089524000099 |
| _version_ | 1797220191339282432 |
|---|---|
| author | Yu Kataoka Satoshi Kitahara Sayaka Funabashi Hisashi Makino Masaki Matsubara Miki Matsuo Yoko Omura-Ohata Ryo Koezuka Mayu Tochiya Tamiko Tamanaha Tsutomu Tomita Kyoko Honda-Kohmo Michio Noguchi Kota Murai Kenichiro Sawada Takamasa Iwai Hideo Matama Satoshi Honda Masashi Fujino Kazuhiro Nakao Shuichi Yoneda Kensuke Takagi Fumiyuki Otsuka Yasuhide Asaumi Kiminori Hosoda Stephen J. Nicholls Satoshi Yasuda Teruo Noguchi |
| author_facet | Yu Kataoka Satoshi Kitahara Sayaka Funabashi Hisashi Makino Masaki Matsubara Miki Matsuo Yoko Omura-Ohata Ryo Koezuka Mayu Tochiya Tamiko Tamanaha Tsutomu Tomita Kyoko Honda-Kohmo Michio Noguchi Kota Murai Kenichiro Sawada Takamasa Iwai Hideo Matama Satoshi Honda Masashi Fujino Kazuhiro Nakao Shuichi Yoneda Kensuke Takagi Fumiyuki Otsuka Yasuhide Asaumi Kiminori Hosoda Stephen J. Nicholls Satoshi Yasuda Teruo Noguchi |
| author_sort | Yu Kataoka |
| collection | DOAJ |
| description | Background and aims: Randomized clinical trials have demonstrated the ability of glucagon-like peptide-1 analogues (GLP-1RAs) to reduce atherosclerotic cardiovascular disease events in patients with type 2 diabetes (T2D). How GLP-1RAs modulate diabetic atherosclerosis remains to be determined yet. Methods: The OPTIMAL study was a prospective randomized controlled study to compare the efficacy of 48-week continuous glucose monitoring- and HbA1c-guided glycemic control on near infrared spectroscopty (NIRS)/intravascular ultrasound (IVUS)-derived plaque measures in 94 statin-treated patients with T2D (jRCT1052180152, UMIN000036721). Of these, 78 patients with evaluable serial NIRS/IVUS images were analyzed to compare plaque measures between those treated with (n = 16) and without GLP-1RAs (n = 72). Results: All patients received a statin, and on-treatment LDL-C levels were similar between the groups (66.9 ± 11.6 vs. 68.1 ± 23.2 mg/dL, p = 0.84). Patients receiving GLP-1RAs demonstrated a greater reduction of HbA1c [-1.0 (-1.4 to −0.5) vs. −0.4 (-0.6 to −0.2)%, p = 0.02] and were less likely to demonstrate a glucose level >180 mg/dL [-7.5 (-14.9 to −0.1) vs. 1.1 (-2.0 - 4.2)%, p = 0.04], accompanied by a significant decrease in remnant cholesterol levels [-3.8 (-6.3 to −1.3) vs. −0.1 (-0.8 - 1.1)mg/dL, p = 0.008]. On NIRS/IVUS imaging analysis, the change in percent atheroma volume did not differ between the groups (−0.9 ± 0.25 vs. −0.2 ± 0.2%, p = 0.23). However, GLP-1RA treated patients demonstrated a greater frequency of maxLCBI4mm regression (85.6 ± 0.1 vs. 42.0 ± 0.6%, p = 0.01). Multivariate analysis demonstrated that the GLP-1RA use was independently associated with maxLCBI4mm regression (odds ratio = 4.41, 95%CI = 1.19–16.30, p = 0.02). Conclusions: In statin-treated patients with T2D and CAD, GLP-1RAs produced favourable changes in lipidic plaque materials, consistent with its stabilization. |
| first_indexed | 2024-04-24T12:45:37Z |
| format | Article |
| id | doaj.art-409a421a06d648bab589ebcb9fd6fd88 |
| institution | Directory Open Access Journal |
| issn | 2667-0895 |
| language | English |
| last_indexed | 2024-04-24T12:45:37Z |
| publishDate | 2024-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Atherosclerosis Plus |
| spelling | doaj.art-409a421a06d648bab589ebcb9fd6fd882024-04-07T04:36:57ZengElsevierAtherosclerosis Plus2667-08952024-06-015616Glucagon-like Peptide-1 analogues and delipidation of coronary atheroma in statin-treated type 2 diabetic patients with coronary artery disease: The prespecified sub-analysis of the OPTIMAL randomized clinical trialYu Kataoka0Satoshi Kitahara1Sayaka Funabashi2Hisashi Makino3Masaki Matsubara4Miki Matsuo5Yoko Omura-Ohata6Ryo Koezuka7Mayu Tochiya8Tamiko Tamanaha9Tsutomu Tomita10Kyoko Honda-Kohmo11Michio Noguchi12Kota Murai13Kenichiro Sawada14Takamasa Iwai15Hideo Matama16Satoshi Honda17Masashi Fujino18Kazuhiro Nakao19Shuichi Yoneda20Kensuke Takagi21Fumiyuki Otsuka22Yasuhide Asaumi23Kiminori Hosoda24Stephen J. Nicholls25Satoshi Yasuda26Teruo Noguchi27Department of Cardiovascular Medicine, National Cerebral & Cardiovascular Centre, Suita, Osaka, Japan; Corresponding author. Department of Cardiovascular Medicine, National Cerebral & Cardiovascular Center, 6Kishibe-shinmachi, Suita, Osaka, 564-8565, JapanDepartment of Cardiovascular Medicine, National Cerebral & Cardiovascular Centre, Suita, Osaka, Japan; Department of Cardiovascular Medicine, Kashiwa Kousei General Hospital, Kashiwa, JapanDepartment of Cardiovascular Medicine, National Cerebral & Cardiovascular Centre, Suita, Osaka, Japan; Department of Cardiovascular Medicine, Kyorin University, Mitaka, Tokyo, JapanDivision of Diabetes and Lipid Metabolism, National Cerebral & Cardiovascular Center, Suita, Osaka, JapanDivision of Diabetes and Lipid Metabolism, National Cerebral & Cardiovascular Center, Suita, Osaka, JapanDivision of Diabetes and Lipid Metabolism, National Cerebral & Cardiovascular Center, Suita, Osaka, JapanDivision of Diabetes and Lipid Metabolism, National Cerebral & Cardiovascular Center, Suita, Osaka, JapanDivision of Diabetes and Lipid Metabolism, National Cerebral & Cardiovascular Center, Suita, Osaka, JapanDivision of Diabetes and Lipid Metabolism, National Cerebral & Cardiovascular Center, Suita, Osaka, JapanDivision of Diabetes and Lipid Metabolism, National Cerebral & Cardiovascular Center, Suita, Osaka, JapanDivision of Diabetes and Lipid Metabolism, National Cerebral & Cardiovascular Center, Suita, Osaka, JapanDivision of Diabetes and Lipid Metabolism, National Cerebral & Cardiovascular Center, Suita, Osaka, JapanDivision of Diabetes and Lipid Metabolism, National Cerebral & Cardiovascular Center, Suita, Osaka, JapanDepartment of Cardiovascular Medicine, National Cerebral & Cardiovascular Centre, Suita, Osaka, JapanDepartment of Cardiovascular Medicine, National Cerebral & Cardiovascular Centre, Suita, Osaka, JapanDepartment of Cardiovascular Medicine, National Cerebral & Cardiovascular Centre, Suita, Osaka, JapanDepartment of Cardiovascular Medicine, National Cerebral & Cardiovascular Centre, Suita, Osaka, JapanDepartment of Cardiovascular Medicine, National Cerebral & Cardiovascular Centre, Suita, Osaka, JapanVictorian Heart Institute, Monash University, Melbourne, AustraliaDepartment of Cardiovascular Medicine, National Cerebral & Cardiovascular Centre, Suita, Osaka, JapanDepartment of Cardiovascular Medicine, National Cerebral & Cardiovascular Centre, Suita, Osaka, JapanDepartment of Cardiovascular Medicine, National Cerebral & Cardiovascular Centre, Suita, Osaka, JapanDepartment of Cardiovascular Medicine, National Cerebral & Cardiovascular Centre, Suita, Osaka, JapanDepartment of Cardiovascular Medicine, National Cerebral & Cardiovascular Centre, Suita, Osaka, JapanDivision of Diabetes and Lipid Metabolism, National Cerebral & Cardiovascular Center, Suita, Osaka, JapanVictorian Heart Institute, Monash University, Melbourne, AustraliaDepartment of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, JapanDepartment of Cardiovascular Medicine, National Cerebral & Cardiovascular Centre, Suita, Osaka, JapanBackground and aims: Randomized clinical trials have demonstrated the ability of glucagon-like peptide-1 analogues (GLP-1RAs) to reduce atherosclerotic cardiovascular disease events in patients with type 2 diabetes (T2D). How GLP-1RAs modulate diabetic atherosclerosis remains to be determined yet. Methods: The OPTIMAL study was a prospective randomized controlled study to compare the efficacy of 48-week continuous glucose monitoring- and HbA1c-guided glycemic control on near infrared spectroscopty (NIRS)/intravascular ultrasound (IVUS)-derived plaque measures in 94 statin-treated patients with T2D (jRCT1052180152, UMIN000036721). Of these, 78 patients with evaluable serial NIRS/IVUS images were analyzed to compare plaque measures between those treated with (n = 16) and without GLP-1RAs (n = 72). Results: All patients received a statin, and on-treatment LDL-C levels were similar between the groups (66.9 ± 11.6 vs. 68.1 ± 23.2 mg/dL, p = 0.84). Patients receiving GLP-1RAs demonstrated a greater reduction of HbA1c [-1.0 (-1.4 to −0.5) vs. −0.4 (-0.6 to −0.2)%, p = 0.02] and were less likely to demonstrate a glucose level >180 mg/dL [-7.5 (-14.9 to −0.1) vs. 1.1 (-2.0 - 4.2)%, p = 0.04], accompanied by a significant decrease in remnant cholesterol levels [-3.8 (-6.3 to −1.3) vs. −0.1 (-0.8 - 1.1)mg/dL, p = 0.008]. On NIRS/IVUS imaging analysis, the change in percent atheroma volume did not differ between the groups (−0.9 ± 0.25 vs. −0.2 ± 0.2%, p = 0.23). However, GLP-1RA treated patients demonstrated a greater frequency of maxLCBI4mm regression (85.6 ± 0.1 vs. 42.0 ± 0.6%, p = 0.01). Multivariate analysis demonstrated that the GLP-1RA use was independently associated with maxLCBI4mm regression (odds ratio = 4.41, 95%CI = 1.19–16.30, p = 0.02). Conclusions: In statin-treated patients with T2D and CAD, GLP-1RAs produced favourable changes in lipidic plaque materials, consistent with its stabilization.http://www.sciencedirect.com/science/article/pii/S2667089524000099Glucagon-like peptide-1 analoguesLipidic plaqueCoronary atherosclerosisType 2 diabetes mellitusIntravascular ultrasoundNear-infrared spectroscopy |
| spellingShingle | Yu Kataoka Satoshi Kitahara Sayaka Funabashi Hisashi Makino Masaki Matsubara Miki Matsuo Yoko Omura-Ohata Ryo Koezuka Mayu Tochiya Tamiko Tamanaha Tsutomu Tomita Kyoko Honda-Kohmo Michio Noguchi Kota Murai Kenichiro Sawada Takamasa Iwai Hideo Matama Satoshi Honda Masashi Fujino Kazuhiro Nakao Shuichi Yoneda Kensuke Takagi Fumiyuki Otsuka Yasuhide Asaumi Kiminori Hosoda Stephen J. Nicholls Satoshi Yasuda Teruo Noguchi Glucagon-like Peptide-1 analogues and delipidation of coronary atheroma in statin-treated type 2 diabetic patients with coronary artery disease: The prespecified sub-analysis of the OPTIMAL randomized clinical trial Atherosclerosis Plus Glucagon-like peptide-1 analogues Lipidic plaque Coronary atherosclerosis Type 2 diabetes mellitus Intravascular ultrasound Near-infrared spectroscopy |
| title | Glucagon-like Peptide-1 analogues and delipidation of coronary atheroma in statin-treated type 2 diabetic patients with coronary artery disease: The prespecified sub-analysis of the OPTIMAL randomized clinical trial |
| title_full | Glucagon-like Peptide-1 analogues and delipidation of coronary atheroma in statin-treated type 2 diabetic patients with coronary artery disease: The prespecified sub-analysis of the OPTIMAL randomized clinical trial |
| title_fullStr | Glucagon-like Peptide-1 analogues and delipidation of coronary atheroma in statin-treated type 2 diabetic patients with coronary artery disease: The prespecified sub-analysis of the OPTIMAL randomized clinical trial |
| title_full_unstemmed | Glucagon-like Peptide-1 analogues and delipidation of coronary atheroma in statin-treated type 2 diabetic patients with coronary artery disease: The prespecified sub-analysis of the OPTIMAL randomized clinical trial |
| title_short | Glucagon-like Peptide-1 analogues and delipidation of coronary atheroma in statin-treated type 2 diabetic patients with coronary artery disease: The prespecified sub-analysis of the OPTIMAL randomized clinical trial |
| title_sort | glucagon like peptide 1 analogues and delipidation of coronary atheroma in statin treated type 2 diabetic patients with coronary artery disease the prespecified sub analysis of the optimal randomized clinical trial |
| topic | Glucagon-like peptide-1 analogues Lipidic plaque Coronary atherosclerosis Type 2 diabetes mellitus Intravascular ultrasound Near-infrared spectroscopy |
| url | http://www.sciencedirect.com/science/article/pii/S2667089524000099 |
| work_keys_str_mv | AT yukataoka glucagonlikepeptide1analoguesanddelipidationofcoronaryatheromainstatintreatedtype2diabeticpatientswithcoronaryarterydiseasetheprespecifiedsubanalysisoftheoptimalrandomizedclinicaltrial AT satoshikitahara glucagonlikepeptide1analoguesanddelipidationofcoronaryatheromainstatintreatedtype2diabeticpatientswithcoronaryarterydiseasetheprespecifiedsubanalysisoftheoptimalrandomizedclinicaltrial AT sayakafunabashi glucagonlikepeptide1analoguesanddelipidationofcoronaryatheromainstatintreatedtype2diabeticpatientswithcoronaryarterydiseasetheprespecifiedsubanalysisoftheoptimalrandomizedclinicaltrial AT hisashimakino glucagonlikepeptide1analoguesanddelipidationofcoronaryatheromainstatintreatedtype2diabeticpatientswithcoronaryarterydiseasetheprespecifiedsubanalysisoftheoptimalrandomizedclinicaltrial AT masakimatsubara glucagonlikepeptide1analoguesanddelipidationofcoronaryatheromainstatintreatedtype2diabeticpatientswithcoronaryarterydiseasetheprespecifiedsubanalysisoftheoptimalrandomizedclinicaltrial AT mikimatsuo glucagonlikepeptide1analoguesanddelipidationofcoronaryatheromainstatintreatedtype2diabeticpatientswithcoronaryarterydiseasetheprespecifiedsubanalysisoftheoptimalrandomizedclinicaltrial AT yokoomuraohata glucagonlikepeptide1analoguesanddelipidationofcoronaryatheromainstatintreatedtype2diabeticpatientswithcoronaryarterydiseasetheprespecifiedsubanalysisoftheoptimalrandomizedclinicaltrial AT ryokoezuka glucagonlikepeptide1analoguesanddelipidationofcoronaryatheromainstatintreatedtype2diabeticpatientswithcoronaryarterydiseasetheprespecifiedsubanalysisoftheoptimalrandomizedclinicaltrial AT mayutochiya glucagonlikepeptide1analoguesanddelipidationofcoronaryatheromainstatintreatedtype2diabeticpatientswithcoronaryarterydiseasetheprespecifiedsubanalysisoftheoptimalrandomizedclinicaltrial AT tamikotamanaha glucagonlikepeptide1analoguesanddelipidationofcoronaryatheromainstatintreatedtype2diabeticpatientswithcoronaryarterydiseasetheprespecifiedsubanalysisoftheoptimalrandomizedclinicaltrial AT tsutomutomita glucagonlikepeptide1analoguesanddelipidationofcoronaryatheromainstatintreatedtype2diabeticpatientswithcoronaryarterydiseasetheprespecifiedsubanalysisoftheoptimalrandomizedclinicaltrial AT kyokohondakohmo glucagonlikepeptide1analoguesanddelipidationofcoronaryatheromainstatintreatedtype2diabeticpatientswithcoronaryarterydiseasetheprespecifiedsubanalysisoftheoptimalrandomizedclinicaltrial AT michionoguchi glucagonlikepeptide1analoguesanddelipidationofcoronaryatheromainstatintreatedtype2diabeticpatientswithcoronaryarterydiseasetheprespecifiedsubanalysisoftheoptimalrandomizedclinicaltrial AT kotamurai glucagonlikepeptide1analoguesanddelipidationofcoronaryatheromainstatintreatedtype2diabeticpatientswithcoronaryarterydiseasetheprespecifiedsubanalysisoftheoptimalrandomizedclinicaltrial AT kenichirosawada glucagonlikepeptide1analoguesanddelipidationofcoronaryatheromainstatintreatedtype2diabeticpatientswithcoronaryarterydiseasetheprespecifiedsubanalysisoftheoptimalrandomizedclinicaltrial AT takamasaiwai glucagonlikepeptide1analoguesanddelipidationofcoronaryatheromainstatintreatedtype2diabeticpatientswithcoronaryarterydiseasetheprespecifiedsubanalysisoftheoptimalrandomizedclinicaltrial AT hideomatama glucagonlikepeptide1analoguesanddelipidationofcoronaryatheromainstatintreatedtype2diabeticpatientswithcoronaryarterydiseasetheprespecifiedsubanalysisoftheoptimalrandomizedclinicaltrial AT satoshihonda glucagonlikepeptide1analoguesanddelipidationofcoronaryatheromainstatintreatedtype2diabeticpatientswithcoronaryarterydiseasetheprespecifiedsubanalysisoftheoptimalrandomizedclinicaltrial AT masashifujino glucagonlikepeptide1analoguesanddelipidationofcoronaryatheromainstatintreatedtype2diabeticpatientswithcoronaryarterydiseasetheprespecifiedsubanalysisoftheoptimalrandomizedclinicaltrial AT kazuhironakao glucagonlikepeptide1analoguesanddelipidationofcoronaryatheromainstatintreatedtype2diabeticpatientswithcoronaryarterydiseasetheprespecifiedsubanalysisoftheoptimalrandomizedclinicaltrial AT shuichiyoneda glucagonlikepeptide1analoguesanddelipidationofcoronaryatheromainstatintreatedtype2diabeticpatientswithcoronaryarterydiseasetheprespecifiedsubanalysisoftheoptimalrandomizedclinicaltrial AT kensuketakagi glucagonlikepeptide1analoguesanddelipidationofcoronaryatheromainstatintreatedtype2diabeticpatientswithcoronaryarterydiseasetheprespecifiedsubanalysisoftheoptimalrandomizedclinicaltrial AT fumiyukiotsuka glucagonlikepeptide1analoguesanddelipidationofcoronaryatheromainstatintreatedtype2diabeticpatientswithcoronaryarterydiseasetheprespecifiedsubanalysisoftheoptimalrandomizedclinicaltrial AT yasuhideasaumi glucagonlikepeptide1analoguesanddelipidationofcoronaryatheromainstatintreatedtype2diabeticpatientswithcoronaryarterydiseasetheprespecifiedsubanalysisoftheoptimalrandomizedclinicaltrial AT kiminorihosoda glucagonlikepeptide1analoguesanddelipidationofcoronaryatheromainstatintreatedtype2diabeticpatientswithcoronaryarterydiseasetheprespecifiedsubanalysisoftheoptimalrandomizedclinicaltrial AT stephenjnicholls glucagonlikepeptide1analoguesanddelipidationofcoronaryatheromainstatintreatedtype2diabeticpatientswithcoronaryarterydiseasetheprespecifiedsubanalysisoftheoptimalrandomizedclinicaltrial AT satoshiyasuda glucagonlikepeptide1analoguesanddelipidationofcoronaryatheromainstatintreatedtype2diabeticpatientswithcoronaryarterydiseasetheprespecifiedsubanalysisoftheoptimalrandomizedclinicaltrial AT teruonoguchi glucagonlikepeptide1analoguesanddelipidationofcoronaryatheromainstatintreatedtype2diabeticpatientswithcoronaryarterydiseasetheprespecifiedsubanalysisoftheoptimalrandomizedclinicaltrial |